Innate Pharma (IPHA) Total Current Liabilities (2017 - 2025)

Innate Pharma has reported Total Current Liabilities for 9 years, with the latest figure at $42.7 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 21.04% year-over-year to $42.7 million; the trailing twelve-month figure through Dec 2025 stood at $42.7 million (up 21.04% YoY), and the FY2025 full-year result was $42.7 million, up 21.04% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $42.7 million, up from $33.3 million in the prior quarter.
• The five-year high for Total Current Liabilities was $91.4 million in Q4 2021, with the low at $33.3 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $49.9 million across 5 years, with a median of $42.4 million in 2022.
• The largest YoY upside for Total Current Liabilities was 68.5% in 2021 against a maximum downside of 99.94% in 2021.
• Innate Pharma's Total Current Liabilities stood at $91.4 million in 2021, then slumped by 53.85% to $42.2 million in 2022, then climbed by 1.12% to $42.6 million in 2023, then decreased by 17.36% to $35.2 million in 2024, then increased by 21.04% to $42.7 million in 2025.
• The last three Total Current Liabilities figures came in at $42.7 million (Q4 2025), $33.3 million (Q2 2025), and $35.2 million (Q4 2024), per Business Quant data.